Evaluation of the effect of acetazolamide versus mannitol on cisplatin-induced nephrotoxicity, a pilot study

Retrospective Analysis of Cisplatin Nephrotoxicity in Patients With Head and Neck Cancer Receiving Outpatient Treatment With Concurrent High-dose Cisplatin and Radiotherapy

(2018) Jennifer Faig et al.   AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS

A Systematic Review of Strategies to Prevent Cisplatin‐Induced Nephrotoxicity

(2017) Daniel J. Crona et al.   ONCOLOGIST

Nephrotoxicity of cisplatin combination chemotherapy in thoracic malignancy patients with CKD risk factors

(2016) Ko Sato et al.   BMC CANCER

Incidence of Cisplatin-Induced Nephrotoxicity and Associated Factors among Cancer Patients in Indonesia

(2015) Yenny Prasaja et al.   Asian Pacific Journal of Cancer Prevention

Rates of Renal Toxicity in Cancer Patients Receiving Cisplatin With and Without Mannitol

(2014) Katherine P. Morgan et al.   ANNALS OF PHARMACOTHERAPY

Risk Factors for Cisplatin-Induced Nephrotoxicity and Potential of Magnesium Supplementation for Renal Protection

(2014) Yasuhiro Kidera et al.   PLoS One

Pathophysiology of Cisplatin-Induced Acute Kidney Injury

(2014) Abdullah Ozkok et al.   Biomed Research International

The Role of Mannitol as a Nephroprotectant in Patients Receiving Cisplatin Therapy

(2012) K. P. Morgan et al.   ANNALS OF PHARMACOTHERAPY

Prediction of nephrotoxicity induced by cisplatin combination chemotherapy in gastric cancer patients

(2011) Hyung Hwan Moon   WORLD JOURNAL OF GASTROENTEROLOGY

Mechanisms of Cisplatin Nephrotoxicity

(2010) Ronald P. Miller et al.   Toxins

Contribution of Organic Cation Transporter 2 (OCT2) to Cisplatin-Induced Nephrotoxicity

(2009) K K Filipski et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Prevention of cisplatin nephrotoxicity: state of the art and recommendations from the European Society of Clinical Pharmacy Special Interest Group on Cancer Care

(2008) Vincent Launay-Vacher et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY